Clinical Trials
Enrolling Trials
121-130 of 180
13.1.2 Upgrade Testing
New Agents
Adult
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Velos Only PM Study - TEST - Post-update CTMS Message Queue moved to new DEV server.
Testing Project Manager API after 13.1.2 upgrade
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
iRIS Insert Test
Testing EDIT
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CCEPH Insert Test
Testing
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
NFMC Insert Test
qaqa27
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CPMR Insert Test UPDATE 7/16/2025
CPMR Insert Test
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
08272025 - 200 character length title 08272025 - 200 character length title08272025 - 200 character length title08272025 - 200 character length title08272025 - 200 character length title08272025 - 200
Velos project with PIVelos project with PI
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
08282025 - 255 character length title 08282025 - 255 character length title08282025 - 255 character length title08282025 - 255 character length title08282025 - 255 character length title08282025 - 255 character length title08282025 - 255 character length1
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08282025 - IRDL CC Test08
tbd
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
TEST - NFMC Cost Center
Testing NFMC Cost Center 605
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449